NASDAQ · SSIIHealthcareSurgical Instruments

SS Innovations International financials

$2.890.00%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Q2 '25
Jun 30
Revenue$13.9M$11.1M$14.5M$12.8M$10.0M
Gross profit$7.1M$5.3M$6.4M$6.2M$5.9M
Gross margin50.9%48.0%43.9%48.1%59.1%
Operating income-$93.2K-$3.6M-$735.0K-$1.8M$1.7M
Net income-$2.7M-$3.6M-$2.5M-$3.7M-$256.7K
Net margin−19.1%−32.3%−17.0%−29.0%−2.6%
Diluted EPS$-0.01$-0.02$-0.01$-0.02$0.00
EBITDA$253.2K-$3.3M-$425.5K-$1.5M$2.0M
Operating cash flow-$4.2M-$2.3M-$1.5M-$7.5M-$3.5M
Free cash flow-$4.4M-$2.4M-$3.2M-$8.2M-$3.8M
Diluted shares209.4M205.3M200.5M202.9M202.8M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30
Cash & equivalents$13.6M$16.0M$3.2M$5.7M$11.4M
Short-term investments$0.00$0.00$0.00$0.00$0.00
Total debt$14.6M$11.2M$11.4M$10.1M$7.0M
Total assets$97.0M$90.5M$74.2M$69.6M$70.0M
Total liabilities$43.6M$36.0M$36.0M$29.9M$28.0M
Shareholders' equity$53.4M$54.5M$38.2M$39.6M$42.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology